Welcome to our dedicated page for Amarin SEC filings (Ticker: AMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amarin Corporation plc (NASDAQ: AMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amarin is a global pharmaceutical company focused on cardiovascular disease and the commercialization of its icosapent ethyl product, VASCEPA/VAZKEPA. Its filings offer detailed insight into how the business is structured, how key agreements are arranged and how financial performance is reported.
Investors can use this page to review current reports on Form 8-K, where Amarin discloses material events such as quarterly financial results, global restructuring actions and major licensing arrangements. For example, a Form 8-K describes the exclusive long-term license and supply agreement with Recordati to develop and commercialize VAZKEPA in 59 European-focused countries, as well as the associated global restructuring plan aimed at reducing operating costs. Other 8-K filings address financial results for specific quarters and executive appointments.
In addition to 8-Ks, Amarin’s periodic reports on Form 10-K and Form 10-Q (referenced in its press releases) contain more comprehensive discussions of revenue from VASCEPA/VAZKEPA, licensing and royalty income, operating expenses, restructuring charges and risk factors related to cardiovascular therapeutics and global commercialization. These documents are central for understanding the company’s balance sheet, cash position, cost structure and exposure to clinical, regulatory and market risks.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as the nature of material agreements, the scale and timing of restructuring plans, and the implications of licensing deals for future revenue streams. Users can quickly identify items related to Amarin’s cardiovascular franchise, including references to VASCEPA/VAZKEPA, global partners and restructuring initiatives, while retaining the ability to drill down into the full SEC documents for complete context.
Amarin Corporation plc details its global cardiovascular franchise built around VASCEPA/VAZKEPA in this annual report, highlighting broad regulatory approvals in the U.S., Europe, China and other regions based on the REDUCE-IT outcomes trial.
The company operates a single business segment, supplying icosapent ethyl to partners worldwide while facing extensive U.S. generic competition in the MARINE indication and branded and generic lipid therapies. As of June 30, 2025, non-affiliate equity market value was approximately $334.7 million, and 416,079,145 ordinary shares were outstanding as of February 20, 2026, including 20,364,324 represented by ADSs.
Amarin notes a global restructuring plan announced on June 24, 2025 tied to its exclusive license and supply agreement with Recordati for 59 European countries, expected to reduce annual operating costs by about $70 million. Inventory totaled $195.9 million as of December 31, 2025, and the report emphasizes extensive clinical data, long European exclusivity to 2039, and ongoing regulatory and competitive risks.
Amarin Corporation plc reported fourth-quarter 2025 net revenue of $49.2 million, down 21% from a year earlier, but sharply narrowed its net loss to $1.2 million. Operating loss improved to $6.3 million from $52.5 million as restructuring and cost-cutting lowered expenses.
Product revenue declined across the U.S., Europe and Rest-of-World, while licensing and royalty revenue rose to $2.7 million. Amarin realized $31 million of an expected $70 million in restructuring-related cost savings and ended 2025 with $302.6 million in cash and investments and no debt.
For full-year 2025, net revenue was $213.6 million and GAAP net loss was $38.8 million, but non-GAAP adjusted net income reached $16.2 million. Management highlighted a return to positive cash flow in the fourth quarter and a long-term European licensing and supply agreement for VAZKEPA® with Recordati.
Amarin Corporation plc President and CEO Aaron Berg reported several equity compensation events and related share movements. On February 1, 2026, he received 26,793 restricted stock units (RSUs) and a stock option for 120,566 American Depositary Shares (ADSs) under Amarin’s 2020 Stock Incentive Plan.
Each RSU represents a contingent right to receive twenty ordinary shares or cash. On January 31, 2026, previously granted RSUs vested, converting into 2,246 ADSs and 1,933 ADSs. The company withheld 1,235 ADSs and 1,063 ADSs at $15.42 per ADS to cover tax liabilities, which is explicitly described as not being market sales.
The filing notes a prior ADS ratio change effective April 11, 2025, where one ADS now represents twenty ordinary shares, and all reported amounts reflect this adjusted ratio.
Amarin Corporation’s EVP and Chief Legal Officer, Jonathan Provoost, reported new equity awards dated February 1, 2026. He received 8,013 Restricted Stock Units (RSUs) and a stock option for 36,060 American Depositary Shares (ADSs) under the 2020 Stock Incentive Plan.
The 8,013 RSUs vest in three equal installments on January 31, 2027, January 31, 2028 and January 31, 2029. The 36,060 ADS option vests over three years, with 33% vesting on the first anniversary of the grant date and the remainder vesting quarterly over the following eight calendar quarters. The filing notes that, effective April 11, 2025, one ADS represents twenty ordinary shares and that the reported award amounts already reflect this ratio change.
Amarin Corporation’s SVP and CFO Peter L. Fishman reported equity compensation and related share activity. On February 1, 2026, he received 6,167 restricted stock units (RSUs) and a stock option for 27,750 American Depositary Shares (ADSs) with a $14.99 exercise price, all under the company’s stock plan.
These RSUs vest in three equal installments on January 31 of 2027, 2028, and 2029. On January 31, 2026, previously granted RSUs vested, resulting in the issuance of 563 and 1,833 ADSs, with 310 and 1,008 ADSs withheld at $15.42 per share to cover tax obligations rather than sold in the market.
Amarin Corporation executive Steven B. Ketchum reported multiple equity compensation events and related share movements. On January 31, 2026, previously granted RSUs vested, converting into 2,246 and 1,933 American Depositary Shares (ADS). The company withheld 1,235 and 1,062 ADS at $15.42 per ADS to cover taxes, leaving Ketchum holding about 40,879 ADS directly.
On February 1, 2026, Ketchum received new awards under Amarin’s 2020 Stock Incentive Plan: 8,013 Restricted Stock Units and a stock option for 36,060 ADS with an exercise price of $14.99 per ADS, vesting over three years. Each ADS currently represents twenty Ordinary Shares following an earlier ADS ratio change, and each RSU corresponds to twenty Ordinary Shares or cash at the company’s discretion.
Amarin Corporation’s EVP and Chief Operating Officer David Paul Keenan reported routine equity compensation activity and tax withholding around RSU vesting. On January 31, 2026, previously granted restricted stock units converted into American Depositary Shares (ADSs), with 2,246 ADSs and 1,933 ADSs delivered and portions of each vest used to cover taxes through share withholding at $15.42 per ADS.
On February 1, 2026, Keenan received a new grant of 8,013 restricted stock units and 30,060 stock options under Amarin’s 2020 Stock Incentive Plan, with the RSUs and options scheduled to vest over three years. Each RSU represents a contingent right to receive twenty ordinary shares or cash, reflecting a prior change so that 1 ADS equals 20 ordinary shares.
Amarin Corporation plc filed a current report to note that it has released a press release with its preliminary unaudited 2025 financial highlights. The release also summarizes key operational accomplishments for 2025 and outlines the company’s priorities for 2026. This information is being furnished as an exhibit rather than filed, which limits how it is incorporated into other regulatory documents.
Amarin Corporation’s EVP and Chief Operating Officer, Keenan David Paul, reported routine equity compensation activity. On January 2, 2026, 3,688 Restricted Stock Units vested into the right to receive American Depositary Shares at an exercise price of $0.00. These were reflected as 3,688 American Depositary Shares acquired through an option exercise transaction.
To cover tax obligations related to the vesting, the company withheld 1,926 American Depositary Shares at a price of $13.96 per share, which the filing notes was not a market sale. After these transactions, the executive directly owned 9,712 American Depositary Shares and 3,688 RSUs. The filing also reminds investors that one ADS currently represents twenty ordinary shares following an earlier ADS ratio change.
Amarin Corporation EVP and Chief Scientific Officer Steven B. Ketchum reported equity compensation activity involving American Depositary Shares (ADSs) and restricted stock units (RSUs). On January 2, 2026, 3,688 RSUs were credited at an exercise price of $0, each representing a contingent right to receive twenty ordinary shares or cash. The same day, 3,688 ADS were acquired in a transaction coded "M," leaving 41,038 ADS directly held.
A separate transaction coded "F" shows 2,041 ADS withheld at $13.96 per ADS to cover tax liabilities tied to the vesting, reducing directly held ADS to 38,997. These RSUs were part of a 7,376‑unit grant awarded on January 10, 2025 under Amarin’s 2020 Stock Incentive Plan, scheduled to vest 50% on January 2, 2026 and the remainder on July 1, 2026. The company had previously changed its ADS ratio so that one ADS represents twenty ordinary shares, and all reported amounts reflect this ratio.